Clinical Trials Sponsored by Mario Ammirati

Total 1158 results

Mario Ammirati

Withdrawn

The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy

Hypertension

United States
Enrico Ammirati

Completed

IMaging Della PLAcca Carotidea (IMPLAC)

Ischemic Stroke | Atherosclerosis | Carotid Artery Plaque
Consorzio Mario Negri Sud
LifeScan

Completed

Role Of Self-monitoring of Blood Glucose and Intensive Education in Patients With Type 2 Diabetes Not Receiving Insulin (ROSES)

Type 2 Diabetes

Italy
Mirati Therapeutics Inc.

Recruiting

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (202200050434)

Metastatic Lung Cancer | Advanced NSCLC

United States, Spain, Greece, Hungary, France, Italy, Poland
Mirati Therapeutics Inc.

Recruiting

Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Pancreatic Adenocarcinoma | Solid Tumor | Non Small Cell Lung Cancer | Mesothelioma | Advanced Solid Tumor | Malignant Peripheral Nerve Sheath Tumors

United States
Mirati Therapeutics Inc.

Terminated

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

Advanced Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, China, Romania, Netherlands, Hong Kong, Austria, Belgium, Czechia, Hungary, Portugal, Greece, Germany, Ireland, Switze... and more
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Metastatic Colorectal Cancer | Advanced Colorectal Cancer

United States, Denmark, Finland, Italy, Spain, Belgium, Romania, Taiwan, Thailand, France, Germany, Korea, Republic of, China, Malaysia, Hong Kong, Australia, Austria, Puerto Rico, Singapore, Canada, Portugal, Poland, Greece, United Kingdom and more
Mirati Therapeutics Inc.

Completed

A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib

Healthy Adults

United States
Mirati Therapeutics Inc.

Completed

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

Hepatic Impairment

United States
Mirati Therapeutics Inc.

Approved for marketing

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Metastatic Cancer | Advanced Cancer | Malignant Neoplasm

United States
Mirati Therapeutics Inc.

Completed

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Hungary, United Kingdom, Italy, Australia, Taiwan, Poland, Canada
Mirati Therapeutics Inc.

Terminated

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

United States, Canada
Mirati Therapeutics Inc.

Completed

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, Canada
Mirati Therapeutics Inc.

Completed

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Lymphoma

United States, Canada
Mirati Therapeutics Inc.

Terminated

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States, Canada, United Kingdom
Mirati Therapeutics Inc.

Terminated

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Stomach Cancer | Breast Cancer | Gastric Cancer | Lung Cancer | Prostate Cancer | Non-Small-Cell Lung Carcinoma | Prostatic Cancer | Pulmonary Cancer

United States
Mirati Therapeutics Inc.

Recruiting

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Metastatic Cancer | Advanced Cancer | Malignant Neoplasm of Lung

Korea, Republic of, United States, Turkey, France, Taiwan, Spain
Mirati Therapeutics Inc.

Recruiting

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Pancreatic Adenocarcinoma | Solid Tumor | Advanced Solid Tumor | Non-small Cell Lung Cancer | Colo-rectal Cancer

United States
Mirati Therapeutics Inc.

Recruiting

A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Solid Tumor | Non Small Cell Lung Cancer | Advanced Solid Tumor | Colo-rectal Cancer

United States, Puerto Rico
Mirati Therapeutics Inc.

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
Mirati Therapeutics Inc.

Recruiting

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Metastatic Cancer | Advanced Cancer | Malignant Neoplastic Disease

United States, Puerto Rico
Mirati Therapeutics Inc.

Completed

Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States
Mirati Therapeutics Inc.

Terminated

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma Bladder | Urothelial Carcinoma | Urothelial Carcinoma Ureter | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Urethra

United States
Mirati Therapeutics Inc.

Completed

A Study to Explore the Effect of Acid-reducing Agents

Healthy Adults

United States
Mirati Therapeutics Inc.

Terminated

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Hodgkin Lymphoma | Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)

United States
Mirati Therapeutics Inc.

Completed

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

Tumors

United States, Canada
Mirati Therapeutics Inc.

Terminated

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Myelodysplastic Syndromes | Myelogenous Leukemia, Acute

United States, Canada
Mirati Therapeutics Inc.

Completed

Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers

Healthy

Canada
Mirati Therapeutics Inc.

Completed

Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

Advanced Malignancies

United States
Mirati Therapeutics Inc.

Completed

A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

Canada, United States
Mario Negri Institute for Pharmacological Research

Recruiting

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases (ANTHEM)

Healthy | Autosomal Dominant Polycystic Kidney | Atypical Hemolytic Uremic Syndrome | Membranoproliferative Glomerulonephritis

Italy
Mario Negri Institute for Pharmacological Research

Not yet recruiting

Reduction Of Dietary Salt Intake To Control Systolic Blood Pressure In Hypertensive Older Patients (REPRESS)

Hypertension
Mario Negri Institute for Pharmacological Research

Recruiting

B Cells in Idiopathic Nephrotic Syndrome (BLADE)

Nephrotic Syndrome

Italy
Mario Luca Morieri

Recruiting

Genetic-Dependent Cardiovascular Response to PPAR-Alpha Agonist Fenofibrate (MAGNETIC)

Cardiovascular Diseases | Type 2 Diabetes | Pharmacogenomic Drug Interaction

Italy
Mario Negri Institute for Pharmacological Research

Recruiting

Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Gastric Carcinoma.GOETH Study (GOETH)

Stomach Neoplasms

Italy
Mario Boccadoro

Active, not recruiting

Immune Profiling in Multiple Myeloma

Multiple Myeloma

Italy
Mario Negri Institute for Pharmacological Research

Active, not recruiting

Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Admissions of Patients Accessing the Emergency Department (ASST Papa Giovanni XXIII)

Emergency Departments | Evaluation | Quality of Care | Appropriateness

Italy
Mario Negri Institute for Pharmacological Research

Completed

Thyroid Hormones in ADPKD (REORIENTED)

Autosomal Dominant Polycystic Kidney

Italy
Mario Negri Institute for Pharmacological Research

Withdrawn

COVID-19 Algorithm Treatment at Home (COVER-HOME)

COVID-19
Mario Negri Institute for Pharmacological Research

Terminated

Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance (MSC-KTX)

Kidney Transplant

Italy
Mario Boccadoro

Active, not recruiting

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. (FORTE)

MULTIPLE MYELOMA (MM)

Italy
Mario Boccadoro

Completed

Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients (MMpredict)

Multiple Myeloma

Italy
Mario Negri Institute for Pharmacological Research

Terminated

Genetic Study of Nephrolithiasis in Gouty Diathesis

Nephrolithiasis

Italy
Mario Negri Institute for Pharmacological Research

Completed

Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome

Alport Syndrome

Italy
Mario Negri Institute for Pharmacological Research

Completed

A Simple Approach to Prevent Hospitalization for COVID-19 Patients (COVER2)

Covid19

Italy
Mario Negri Institute for Pharmacological Research

Completed

COVID-19 Impact on the Lombardy Region's Emergency System

Covid19

Italy
Mario Negri Institute for Pharmacological Research

Active, not recruiting

Remission Clinic in Proteinuric Chronic Nephropathies

Chronic Kidney Disease

Italy
Mario Negri Institute for Pharmacological Research

Completed

A Simple Approach to Treat COVID-19 Patients at Home. (COVER)

COVID 19

Italy
Mario Negri Institute for Pharmacological Research

Completed

Decision-aid on Breast Cancer Screening

Breast Cancer

Italy

Clinical Trials Sponsored by Mario Ammirati

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations